2024 HIV Mid-Year Market Memo
Introducing the eighth edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...
top of page
A framework to support new product introduction in national health systems
Resource Library
May 6
HIV Drug Resistance Testing Costing Tool
This tool was developed to support national HIV programs and ministries of health to estimate and compare the cost of the following two...
74 views
Jan 30
CHAI ARV Approvals Database
Last Updated: January 2024 A Stringent Regulatory Authority (SRA) is a medicines regulatory authority that enforces and ensures medicines...
138 views
Jan 3
CAB Case Studies from Ethiopia
These Community Advisory Board (CAB) case studies capture highlights of what CAB members considered to be some of the most impactful...
88 views
Dec 14, 2023
Planning Considerations for the Introduction of pALD
This slide deck, presented by CHAI at IPHASA 2023, outlines planning considerations for the introduction of pALD throughout all stages of...
199 views
Dec 14, 2023
CHAI Simple Tool Training Video
The CHAI Simple Tool is a morbidity-based forecasting tool that quantifies ARV needs over a three year period for an HIV/AIDS treatment...
118 views
Oct 31, 2023
2023 HIV Market Report
CHAI is pleased to release the fourteenth issue of our annual HIV market report. This report provides a detailed look at the complex,...
21 views
Oct 20, 2023
Pediatric Treatment Optimization Roadmap
This treatment optimization roadmap is a resource for Ministries of Health and partner organizations. It offers a summary of pediatric...
257 views
Sep 6, 2023
Pediatric DRV/r (pDRV/r) FAQs
This document is meant to answer some of the most common questions that surround pediatric darunavir/ritonavir 120/20mg (pDRV/r) - a new...
151 views
Sep 6, 2023
Pediatric DRV/r (pDRV/r) Product Profile
This product profile provides a clinical overview of the best-in-class protease inhibitor (PI) formulated in a fixed-dose combination...
151 views
Jun 7, 2023
2023 CHAI HIV Mid-Year Market Memo
Introducing the seventh edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...
107 views
Jun 5, 2023
Pediatric ALD (pALD) FAQs
This document is meant to answer some of the most common questions surround the fixed-dose combination of pediatric...
246 views
May 31, 2023
Optimal CAB Case Study: Pediatric Dolutegravir
This case study, developed by the Optimal CAB in Malawi with support from CHAI, outlines the efforts undertaken by Malawi CAB members to...
100 views
May 30, 2023
pALD Product Profile
This product profile provides a clinical overview of the fixed-dose combination of pediatric abacavir/lamivudine/ dolutegravir 60/30/5 mg...
1,029 views
May 24, 2023
GAP-f pALD Introduction and Rollout Planning Considerations for National Programmes
The GAP-f pDTG task team has developed a brief outlining product introduction and rollout considerations for national programmes when...
552 views
May 4, 2023
The Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study
The Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study was conducted in Benin, Nigeria, and Uganda....
259 views
Mar 16, 2023
ARV Procurement Working Group Progress Review
Highlights in trends from adult ARV, pediatric ARV, and advanced HIV disease markets with summaries on APWG key performance indicators.
175 views
Feb 27, 2023
Community Statements on DRV/r Use in 2L
In December 2022, 40+ community groups and an additional 45+ individuals released a community position statement calling on the global...
75 views
Feb 16, 2023
CAB Case Studies from Tanzania
These FASTER and AIDS Free Community Advisory Board (CAB) case studies capture pediatric and adolescent activities to highlight what CAB...
57 views
Feb 16, 2023
CAB Case Studies from Zambia
These FASTER and AIDS Free Community Advisory Board (CAB) case studies capture pediatric and adolescent activities to highlight what CAB...
46 views
bottom of page